Ares Acquisition Corp III is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses... Show more
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where AAC declined for three days, in 1 of 30 cases, the price declined further within the following month. The odds of a continued downward trend are 3%.
The Momentum Indicator moved above the 0 level on September 14, 2026. You may want to consider a long position or call options on AAC as a result. In 1 of 23 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 4%.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. AAC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AAC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock better than average.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.867) is normal, around the industry mean (126.668). P/E Ratio (61.350) is within average values for comparable stocks, (173.382). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (15.932). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (1.790).
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of inpatient substance abuse treatment services
Industry FinancialConglomerates